Celgene Corporation (CELG)

Check out top investors' recommendation for CELG
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and immune-inflammatory related diseases in the United States, Europe, and other countries. Its commercial stage products include REVLIMID, an oral immunomodulatory drug to treat patients with multiple myeloma and transfusion-dependent anemia; VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk myelodysplastic syndromes (MDS), as well as acute myeloid leukemia (AML); ABRAXANE, a solvent-free chemotherapy treatment option for metastatic breast cancer; and THALOMID for multiple myeloma and the cutaneous manifestations of erythema nodosum leprosum. The company’s commercial stage products also comprise ISTODAX to treat cutaneous T-cell lymphoma; POMALYST for the multiple myeloma and myelofibrosis treatment; and FOCALIN, FOCALIN XR, and RITALIN LA products. Its pre clinical and clinical stage products consist of CC-11050, an anti-inflammatory compound; CC-220, an anti-inflammatory product; cellular therapies, such as PDA-001 and PDA-002; CC-486 that is in Phase III trials to treat MDS and AML, as well as in a Phase I trials for the treatment of solid tumor indications; and sotatercept and ACE-536, which are in Phase II trials to treat anemia in patients with blood disorders. The company’s pre clinical and clinical stage products also include CC-223, a dual TORK inhibitor; CC-292, a BTK inhibitor; CC-115, a dual TORK/DNA PK inhibitor; CC-122, a pleiotropic pathway modulator; and EPZ-5676, a DOT1L inhibitor. It has strategic collaborations with bluebird bio, Inc. to discover, develop, and commercialize gene therapies in oncology; FORMA Therapeutics Holdings to discover, develop, and commercialize drug candidates to regulate protein homeostasis; and Concert Pharmaceuticals, Inc. to develop deuterium-modified compounds for cancer and inflammation. The company was founded in 1980 and is headquartered in Summit, New Jersey.
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Ian Somaiya Piper Jaffray Buy   Nov 16, '17     155.00  Nov 16, '18  N/A 
Terence Flynn Goldman Sachs Sell   Oct 27, '17     91.00  Oct 27, '18  N/A 
Adnan Butt RBC Capital Markets Buy   Oct 23, '17     160.00  Oct 23, '18  N/A 
Eric Schmidt Cowen And Company Buy   Oct 20, '17     150.00  Oct 20, '18  N/A 
Geoff Porges High Peaks Buy   Oct 20, '17     156.00  Oct 20, '18  N/A 
Jim Birchenough BMO Capital Markets Buy   Oct 20, '17     163.00  Oct 20, '18  N/A 
Alethia Young Deutsche Bank Securities Buy   Oct 20, '17     145.00  Oct 20, '18  N/A 
Cory Kasimov JPMorgan Buy   Oct 16, '17       Oct 16, '18  N/A 
Ian Somaiya Piper Jaffray Buy   Oct 16, '17     167.00  Oct 16, '18  N/A 
Matthew Harrison UBS Sell   Oct 05, '17     120.00  Oct 05, '18  N/A 
Brian Abrahams Wells Fargo Securities, Llc Buy   Oct 04, '17     173.00  Oct 04, '18  N/A 
Mara Goldstein Cantor Fitzgerald Buy   Sep 26, '17     162.00  Sep 26, '18  N/A 
Michael Yee RBC Capital Markets Buy   Sep 20, '17     160.00  Sep 20, '18  N/A 
Charles Graham Unaffiliated Buy   Sep 16, '17     650.00  Sep 16, '18  N/A 
Ying Huang Barclays Buy   Sep 13, '17       Sep 13, '18  N/A 
Jason Seidl Cowen And Company Buy   Sep 12, '17     150.00  Sep 12, '18  N/A 
Alethia Young Deutsche Bank Securities Buy   Sep 08, '17     156.00  Sep 08, '18  N/A 
Mara Goldstein Cantor Fitzgerald Buy   Aug 22, '17       Aug 22, '18  N/A 
Michael Yee RBC Capital Markets Buy   Aug 13, '17     160.00  Aug 13, '18  N/A 
David Toung Argus Research Company Buy   Jul 31, '17       Jul 31, '18  N/A 
< previous123456789